Drugs that contain Zoledronic Acid

1. List of Reclast drug patents

RECLAST's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987 NOVARTIS Method of administering bisphosphonates
Oct, 2023

(4 months from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(4 years from now)

US7932241

(Pediatric)

NOVARTIS Pharmaceutical products comprising bisphosphonates
Aug, 2028

(5 years from now)

Market Authorisation Date: 16 April, 2007

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of RECLAST before it's patent expiration?
More Information on Dosage

RECLAST family patents

5

United States

5

European Union

3

Japan

3

Australia

2

Canada

2

Slovenia

2

Korea, Republic of

2

Brazil

2

Taiwan

2

China

2

Denmark

2

Spain

2

New Zealand

2

Norway

2

South Africa

2

Russia

2

Israel

1

Slovakia

1

Poland

1

Luxembourg

1

Hong Kong

1

Iceland

1

Morocco

1

Germany

1

Cyprus

1

Czech Republic

1

Malaysia

1

Argentina

1

Hungary

1

Mexico

1

Colombia

1

Ecuador

1

Austria

1

Portugal

1

Tunisia

1

Peru

2. List of Zometa drug patents

ZOMETA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
May, 2025

(1 year, 11 months from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Nov, 2025

(2 years from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(4 years from now)

Market Authorisation Date: 20 August, 2001

Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ZOMETA before it's patent expiration?
More Information on Dosage

ZOMETA family patents

5

United States

4

Japan

3

Australia

3

European Union

2

Canada

2

Brazil

2

China

1

Korea, Republic of

1

United Kingdom

1

Taiwan

1

Iceland

1

Morocco

1

Malaysia

1

Argentina

1

Spain

1

New Zealand

1

Colombia

1

Norway

1

South Africa

1

Ecuador

1

Tunisia

1

Russia

1

Israel

1

Peru

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic